Dr. Huff’s story is being told for the first time, as she requested, in the comprehensive Wall Street Journal article, “Generation Xanax: The Dark Side of America’s Wonder Drug,” by Shalini Ramachandran and Betsy McKay. This is…
A year ago today, we received the devastating news that our beloved medical director, Dr. Christy Huff, had passed away. While heartbreaking, it wasn’t unexpected—Christy had been trapped in an intense setback for months. Tragically,…
The ASAM Joint Clinical Practice Guideline on Benzodiazepine Tapering is now available. Some of us at BIC, including the late Dr. Christy Huff, served voluntarily on the Patients with Lived Experience (PWLE) panel (see our names on page…
A new study, Increased Risk of Sudden Sensorineural Hearing Loss in Patients Receiving Sedative-Hypnotics: A Propensity Score Weighting Cohort Study, by Yang HW and colleagues explores a possible link between benzodiazepine receptor agonists (BZRA) and…
A large-scale exposure-only within-subject time-to-event pharmacoepidemiologic study led by Robert D. Gibbons and Kwan Hur of the University of Chicago, alongside Jill E. Lavigne and J. John Mann of Columbia University, has confirmed alarming links…
On Thursday, December 5, Gail Dawson, NP, a member of the Benzodiazepine Information Coalition (BIC) Medical Advisory Board, delivered a presentation in Toronto, Canada, at the Centre for Rehabilitation and Health’s Holiday Education Session. Her…
On November 12, 2024, the American Society of Addiction Medicine (ASAM) held a meeting with the patient advisory panel, which includes two members of our organization, to discuss the status of the benzodiazepine deprescribing guidelines….
In 2022, our current medical director, Nicole Lamberson, PA, and our late medical director, Dr. Christy Huff, participated in the James Lind Alliance Priority Setting Partnership, known as PROTECT PSP (Priorities for Future Research on…
